EUVIMEDEUVIMED entdecken
Crossref

MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer

Xinzhao Wei, Ken Uchibori, Nobuyuki Kondo, Takahiro Utsumi, Ai Takemoto, Sumie Koike, Satoshi Takagi, Noriko Yanagitani, Makoto Nishio, Ryohei Katayama

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Xinzhao Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Computational…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Nippon Foundation, Kobayashi Foundation for Cancer Research, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently approved RET tyrosine kinase inhibitors (TKIs) have shown promising therapeutic effects against RET-rearranged non-small cell lung cancer (NSCLC) or RET-mutated thyroid cancer. However, resistance develops, limiting long-term efficacy. Although many RET-TKI resistance mechanisms, such as secondary mutations in RET or activation of bypass pathways, are known, some primary or acquired resistance mechanisms are unclear. Here, human genome-wide CRISPR/Cas9 screening was performed to identify genes related to drug-tolerant persister cells. Patient-derived cells with RET-fusion were introduced genome-wide sgRNA library and treated with RET-TKI for 9 days, resulting in the discovery of several candidate genes. Knockout of MED12 or MIG6 significantly increased residual drug-tolerant persister cells under RET-TKI treatment. MIG6 loss induced significant EGFR activation even with low concentrations of EGFR ligands and led to resistance to RET-TKIs. EGFR inhibition with afatinib or cetuximab in combination with RET TKIs was effective in addressing drug persistence. By contrast, a KIF5B-RET positive cells established from a RET-rearranged NSCLC patient, showed significant resistance to RET-TKIs and high dependence on EGFR bypass signaling. Consistently, knocking out EGFR or RET led to high sensitivity to RET or EGFR inhibitor respectively. Here, we have provided a comprehensive analysis of adaptive and acquired resistance against RET-rearranged NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-retCarcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmProtein Kinase InhibitorsHumansAdaptor Proteins, Signal TransducingTumor Suppressor ProteinsErbB ReceptorsCell Line, TumorGene RearrangementCRISPR-Cas SystemsOncogene Proteins, Fusion

Stichwörter der Autor:innen

CRISPR screeningEGFRLung cancerRET-fusionTargeted therapy resistance

Substanzen

Proto-Oncogene Proteins c-retProtein Kinase InhibitorsRET protein, humanERRFI1 protein, humanAdaptor Proteins, Signal TransducingTumor Suppressor ProteinsErbB ReceptorsEGFR protein, humanKIF5B-RET fusion protein, humanOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, T…
  • Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for C…
  • Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuo…
  • Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Förderung

  • Nippon Foundation
  • Kobayashi Foundation for Cancer Research
  • Takeda Science Foundation
  • Japan Agency for Medical Research and Development
  • Mitsubishi Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Wei, X., Uchibori, K., Kondo, N., Utsumi, T., Takemoto, A., Koike, S., Takagi, S., Yanagitani, N., Nishio, M., & Katayama, R. (2024). MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217220

Vancouver

Wei X, Uchibori K, Kondo N, Utsumi T, Takemoto A, Koike S, et al. MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217220

BibTeX
@article{Wei2024,
  author = {Wei, Xinzhao and Uchibori, Ken and Kondo, Nobuyuki and Utsumi, Takahiro and Takemoto, Ai and Koike, Sumie and Takagi, Satoshi and Yanagitani, Noriko and Nishio, Makoto and Katayama, Ryohei},
  title = {MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217220}
}
Kostenlos starten →